FAQ Category: FAQs

For more information contact CT:IQ, info@ctiq.com.au in the first instance. Depending on availability you and your organisation may be able to express interest in joining the Steering Committee or one of the Project Teams (note Project Team Members do not have to represent an organisation or join the Steering Committee to participate in specific project […]

Part of the requirement of the MTPConnect funding agreement is that the 6 projects make a tangible difference to the Clinical Trials Sector. Therefore we have to ensure that we do measure and evaluate carefully the true effects of CT:IQ. We know that this is often difficult to measure and will be a long process, […]

In line with the success of the CTTI US model, recommendations will be published in peer-reviewed journals, feature on the website, in webinars and at professional meetings and conferences. There may be other tools and resources developed for specific projects as required. One factor of success will also be including the ‘change agents’ in the […]

Currently, topics can only be nominated by the Executive or Steering Committee members. This may change as the pilot phase progresses and we may accept topic nominations from the public in the future. See below for more information on how you might be able to get involved with the Steering Committee.

No, CT:IQ will aim to continuously improve, identify and support best practice in the conduct and design of clinical trials. It will develop solutions to the roadblocks and inefficiencies that impede the value and conduct of all clinical trials in Australia.

The CT:IQ project is receiving funding from MTPConnect for a pilot project which will run until December 2019. In order to progress, there is a requirement for the MTP Connect funds to be matched by other sources. The funding supports CT:IQ infrastructure and provides direct project support. The matched funding will be sourced through a […]

It is important to acknowledge CT:IQ has been many years in the making and seeks to emulate the highly successful FDA-funded Clinical Trials Transformation Initiative(CTTI) in the US. CT:IQ is grateful to the CTTI leadership who have provided advice and support and shared materials freely.

Many health innovations fail at the stage of final clinical testing and are slow to be incorporated into standard care, often not due to the lack of effectiveness, but because of flaws in the design, execution and analysis of the trial. Clinical trials have also become increasingly expensive and take longer to complete as the […]

Yes. They are part of the advisory body of CT:IQ who will provide the strategic direction and the ‘conscience’ of the initiative. They are joined by PBAC/MSAC and international experts.

ACTA, along with Bellberry, the George Institute and NHMRC Clinical Trials Centre (NHMRC CTC) were the founding members of CT:IQ. This initiative is complementary to all of the aforementioned organisations and should be viewed as a collaborative platform of which ACTA is one, very important, voice representing clinical trials networks. Our vision is to act […]